A study on the timing of CDK4/6 inhibitor combined chemotherapy based on RB1 phenotype in the treatment of non-small cell lung cancer

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 54c4054a44e91d85664b9d9cb75a4a710c0bdf2f
First added on: Sep 12, 2026